Adriaan Erasmus Basson (0000-0002-7541-8132)

Personal information

Biography

Dr Adriaan E. Basson is a researcher and lecturer in the HIV Pathogenesis Research Unit (Department of Molecular Medicine and Haematology) at the University of the Witwatersrand. He obtained his Ph.D. in Biochemistry at the University of Johannesburg and kicked off his career as research scientist at the University of Pretoria and the National Institute of Communicable Diseases. His research is focused on HIV-1 drug resistance and HIV-1 cure-related research. He strongly believes that research should make some contribution towards public health concerns, and his research projects are directed towards this goal. Molecular (cloning, sequencing) and in vitro cellular assays (toxicity, anti-viral activity) make up some of the fundamental methodologies that he employs on a daily basis. In addition to his enthusiasm for HIV-1 drug resistance and HIV-1 cure-related research, he also has a strong interested in screening novel antiretroviral drugs from both natural and synthetic sources. He is in ongoing collaborations with organic chemists, both locally and internationally, to investigate novel synthetic compounds as potential antiretroviral drugs.

Activities

Collapse all

University of the Witwatersrand: Johannesburg, ZA

2022-08-23 to present | Senior Lecturer/Researcher (Molecular Medicine & Haematology)

Employment

Adriaan Erasmus Basson

https://orcid.org/0000-0002-7541-8132

Personal information

Other IDs

Keywords

Countries

Biography

Activities

Employment (4)

University of the Witwatersrand: Johannesburg, ZA

University of the Witwatersrand: Johannesburg, ZA

National Institute for Communicable Diseases: Johannesburg, Gauteng, ZA

University of Pretoria: Pretoria, Gauteng, ZA

Education and qualifications (4)

Rand Afrikaans University: Johannesburg, Gauteng, ZA

University of Johannesburg: Johannesburg, ZA

Rand Afrikaans University: Johannesburg, Gauteng, ZA

Rand Afrikaans University: Johannesburg, Gauteng, ZA

Professional activities (4)

Molecular Biosciences Research Thrust (MBRT): Johannesburg, Gauteng, ZA

South African HIV Clinicians Society: Johannesburg, Gauteng, ZA

Molecular Biosciences Research Thrust (MBRT): Johannesburg, Gauteng, ZA

Molecular Biosciences Research Thrust (MBRT): Johannesburg, Gauteng, ZA

Funding (10)

Lenacapavir - Pathways to HIV-1 drug resistance

Assessment of the in vitro phenotypic drug susceptibility of HIV-1 subtype C variants to Islatravir (ISL) and Doravirine (DOR).

Screening of novel antiretroviral compounds for activity against HIV-1.

Finding a needle in a haystack: Scavenging for HIV in hard-to-reach tissue compartments.

Genotypic and phenotypic antiretroviral drug susceptibility of HIV-1 in patients failing salvage (3rd-line) therapy

Development and testing of novel non-nucleoside reverse transcriptase inhibitors for HIV-1 subtype C.

What are the fitness characteristics of HIV-1 in patients who re-suppress on the sane ARV regimen?

Phenotypic drug resistance of re-suppressors and first-generation NNRTI resistance mutation combinations.

Will first generation NNRTI-resistant HIV-1 strains be sensitive to second generation NNRTIs?

Investigation of the development of tenofovir drug resistance in HIV-1 subtypes B and C in vitro, with special reference to the K65R resistance mutation.

Works (26)

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine

Expanding the toolbox of metabolically stable lipid prodrug strategies.

Synthesis of novel pyridine and pyrimidine derivatives as potential inhibitors of HIV-1 reverse transcriptase using palladium-catalysed C-N cross-coupling and nucleophilic aromatic substitution reactions

ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.

HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance

Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility

Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant

Palladium-catalysed cross-coupling as a key step in the synthesis of pyridyl-benzamides, -benzylamines and -sulfonamides

The chlorination behaviour and environmental fate of the antiretroviral drug nevirapine in South African surface water.

Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.

Novel indole sulfides as potent HIV-1 NNRTIs.

Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Novel indole based NNRTIs with improved potency against wild type and resistant HIV.

The 2012 southern African ARV drug resistance testing guidelines

Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.

Inhibitory activities of mushroom tyrosine and DOPA oxidation by plant extracts

Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.

Antibacterial activities and cytotoxicity of terpenoids isolated from Spirostachys africana.

Identification of a cytochrome P450 cDNA (CYP98A5) from Phaseolus vulgaris, inducible by 3,5-dichlorosalicylic acid and 2,6-dichloro isonicotinic acid.

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 subtype C Reverse Transcriptase to Islatravir

Peer review (8 reviews for 6 publications/grants)